Medication for opioid use disorder reduces mortality substantially. The gap between that evidence and what is delivered is among the largest in medicine.
Opioid use disorder is where the distance between established evidence and delivered care is widest in American medicine, and where a value-based arrangement can do the most measurable good.
The evidence
A systematic review and meta-analysis of 32 cohort studies involving 150,235 participants and 9,112 deaths across 805,423.6 person-years of follow-up examined mortality with opioid agonist therapy.
The finding: mortality was substantially reduced during time in treatment compared with time out of treatment. The review noted that “the greatest mortality reduction was conferred during the first 4 weeks” and that “relative risk reduction was substantially higher with methadone relative to buprenorphine when time in-treatment was compared to time out-of-treatment.”
The authors also emphasized that “precautions are necessary for the safer implementation of opioid agonist therapy, including baseline assessments of opioid tolerance, ongoing monitoring during the induction period, education of patients about the risk of overdose.”
That combination, large mortality benefit alongside a genuinely risky induction period requiring clinical care, is the honest version of this evidence. Medication for opioid use disorder is not a low-touch intervention that can be handed out safely without support.
What follows for accountable organizations
The implications are unusually concrete:
- Retention is the outcome. Because the benefit accrues during time in treatment, a program that starts many patients and keeps few has not delivered the benefit. Treatment initiation is a process measure; retention at six months is closer to an outcome.
- The first month needs the most support. Both the greatest mortality benefit and the greatest risk sit in the induction period, which argues for intensive contact early rather than a standard follow-up interval.
- Discontinuity is dangerous. A patient who loses coverage, changes plans, or moves and drops out returns to the higher-mortality state. The Medicaid course covered churn as an administrative problem; here it is a clinical one.
Why this belongs in a value-based curriculum
Most of this curriculum concerns spending. This is one of the places where the accountable organization’s tools, care management, outreach, retention tracking, and closing gaps between prescribed and received treatment, map onto a mortality outcome directly.
Worth remembering: substance use disorder treatment is also where the risk of the pattern in Module 3 is most severe. An organization at risk for total cost of care, looking at a population with substance use disorder, will find that these patients are expensive and that reducing their utilization reduces spending. The evidence says the treatment keeps them alive. If ever there were a case for requiring outcome measurement rather than trusting a spending trend, this is it, and the outcome in question is not a symptom score.
Key takeaways
- A meta-analysis of 32 cohort studies found substantial mortality reduction during opioid agonist treatment versus time out of treatment.
- The greatest mortality reduction occurs in the first four weeks, which is also the period requiring the most clinical caution.
- Retention, not initiation, is the outcome that carries the benefit.
- Coverage churn and treatment discontinuity return patients to a higher-mortality state.
Sources
Check your understanding
What does the evidence show about mortality during opioid agonist treatment?
A meta-analysis of 32 cohort studies covering 150,235 participants found substantial mortality reduction during treatment periods, and noted that the greatest mortality reduction was conferred during the first 4 weeks.